AI-Powered Chatbot Integrated With Wearable-Derived Data for Promoting Mental Health Among Finnish Higher Education Students
Mental health problems among adolescents and young adults have increased globally, underscoring the urgent need for accessible, preventive, and systemic approaches to promoting student mental health. This pilot study aims to evaluate the feasibility, conversational quality, and preliminary effectiveness of an AI-powered chatbot integrated with wearable-derived physiological data intervention to provide personalized and timely mental health support for Finnish higher education students. The study explores how real-time stress indicators, such as heart rate variability (HRV), can inform the chatbot's adaptive and proactive interactions to promote students' mental health in daily life.
The study setting will be the Faculty of Medicine, University of Turku in Finland. A total of 15-20 participants will be recruited with convenience sampling for this study. The inclusion criteria for participants are: 1) enrolled students at the Faculty of Medicine, 2) voluntary and consenting, 3) Finnish-speaking, 4) having a smart phone (Android/iOS), and 5) having none to mild levels of psychological distress. Participants who self-report a diagnosis of mental health disorder, or having an acute treatment for mental health will be excluded.
The intervention in this study consists of 4-week daily use of a AI-powered chatbot. In addition to access to the chatbot, a wearable device will be given to each participant to collect physiological data related to their stress (HRV), physical activity and sleep. At the end of week 2 and 3 of the study, participants will receive a personalized report summarizing the data collected by the device. Throughout the intervention period, the research assistant will contact participants once a week to ensure their well-being. At the end of the study, an interview will be arranged with each participant.
The study data includes the conversations with the chatbot, physiological data from the wearable device, daily stress questions, background information questionnaire, Depression Anxiety Stress Scale (DASS-21) (at the beginning of the intervention and at weeks 2 and 4), Chatbot Usability Questionnaire (CUQ) (at weeks 2 and 4) and an end-of-study semi-structured interview.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Anna Axelin
- Phone Number: +358405029905
- Email: anmaax@utu.fi
Study Locations
-
-
-
Turku, Finland
- Recruiting
- University of Turku
-
Contact:
- Anna Axelin
- Phone Number: +358405029905
- Email: anmaax@utu.fi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Study population consists of higher education students.
Description
Inclusion Criteria:
- enrolled students at the Faculty of Medicine (bachelor's, master's, or doctoral level students)
- voluntary and consenting
- Finnish-speaking (native speaker or enrolled in a Finnish study program)
- having a smart phone (Android/iOS)
- having none to mild levels of psychological distress
Exclusion Criteria:
- self-reported diagnosis of mental health disorder, or having an acute treatment for mental health
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Higher education students
|
Daily use of an AI-powered chatbot and a wearable device to collect physiological data related to stress, physical activity and sleep. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Eligibility of participants
Time Frame: 4 weeks
|
The number of individuals screened, the proportion that meets the inclusion criteria, and the main reasons for exclusion will be documented to assess the appropriateness and practicality of the eligibility criteria. |
4 weeks
|
|
Recruitment and retention of participants
Time Frame: 4 weeks
|
The number of participants enrolled, the proportion completing the whole intervention as well as assessments, and attrition rates will be recorded to evaluate recruitment efficiency and participant retention. |
4 weeks
|
|
Engagement of the participants
Time Frame: 4 weeks
|
Quantitative indicators that include the frequency of chatbot interactions, average session length, and response rates will be analyzed to assess adherence to study procedures and sustained engagement over time. |
4 weeks
|
|
Technical performance of the chatbot
Time Frame: 4 weeks
|
System reliability will be examined through logs of technical errors, data integration issues, and chatbot downtime events, providing insights into the stability and operational consistency of the intervention platform. |
4 weeks
|
|
Safety of the chatbot
Time Frame: 4 weeks
|
It will be assessed whether the chatbot's interactions are free from harm and whether it can appropriately identify and manage high-risk user input. Evaluation focuses on the chatbot's ability to detect and respond to indications of severe distress or crisis, such as expressions of self-harm, suicidal ideation, abuse, or other high-risk situations. Following the MHealth-EVAL framework (Chen et al., 2024), responses will be annotated using a binary scale, where "0" indicates the presence of harmful or unsafe content or failure to address crisis cues appropriately, and "1" indicates a safe and supportive response. |
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychological distress
Time Frame: 4 weeks
|
Psychological distress will be assessed using the Depression Anxiety Stress Scales-21 (DASS-21), which is a 21-item self-report instrument measuring three dimensions of negative emotional states: depression, anxiety, and general stress. Each subscale includes seven items rated on a 4-point Likert scale (0-3), with higher scores indicating greater symptom severity. DASS-21 will be administered before, at two weeks, and after the intervention to assess potential changes in participants' psychological stress. |
4 weeks
|
|
Behavioral change and health literacy
Time Frame: 4 weeks
|
At the end of the 4-week intervention, semi-structured interviews will be conducted with each participant individually to gain an in-depth understanding of their experiences with the chatbot as well as any behavioral changes they perceived during the study. In addition, the participants' understanding of AI health literacy will be discussed. |
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TY/2154/2025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Dataset may be made available for secondary use through the international open science repository Dryad. Identifiers will be removed from the dataset to ensure that individual participants cannot be identified. Secondary use of the data requires a permission process that adheres to established research ethics principles.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.